ClinicalTrials.gg
RecruitingNCT06603558Atogepant PMSSUpdated Jul 22, 2026

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine

An observational study in Chronic Migraine, Episodic Migraine and Migraine, sponsored by AbbVie. Recruiting at 36 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by AbbVie · Observational

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Migraine Disorders by AbbVie — 9 open to participants now, 13 under way, 7 of them phase 3. Migraine Disorders · AbbVie.

Planned enrollment
2nd of 14
3,000 · median 431
Started
2024
with 4 others
Observational
14 of 55
4 open now
Primary completion
2029-05
later than 9 of 12 live
Registered
50th of 55
by date

Among the 55 studies in Migraine Disorders by AbbVie, this one is the 2nd largest by planned enrollment of the 14 observational ones that give a count, is one of 5 that started in 2024, is one of 14 observational ones, reaches primary completion later than 9 of the 12 other live ones, and was the 50th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

9 of the 55 studies in Migraine Disorders by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Migraine Disorders by AbbVie, or all of them as a file.
02

Study summary

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.

Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.

Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.

There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

03

Conditions studied

  • Chronic Migraine
  • Episodic Migraine
  • Migraine

Browse trials for

Keywords

  • Chronic Migraine
  • Episodic Migraine
  • Migraine
  • Atogepant
  • Qulipta
  • Aquipta
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants who have been prescribed atogepant for preventive treatment migraine according to the latest approved local label in routine clinical practice.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
  • Participants prescribed atogepant in accordance with the approved local label.

Exclusion criteria

Exclusion Criteria:

  • Participants with any to atogepant as listed on the latest approved local label.
  • Participants currently participating in another clinical research except observational study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,000 participants (estimated)

Groups and cohorts

  • Atogepant

    Participants will receive atogepant as prescribed by their physician according to the local label.

    Drug: Atogepant

Interventions

  • Oral Tablet

    Also known as: Qulipta, Aquipta

06

What researchers measure

Primary outcomes

  1. Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)

    Percentage (%) of participants who reported serious adverse event (SAE)/drug reaction (SADR)

    Time frame: Up to approximately 16 Weeks

  2. Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)

    Percentage (%) of participants who reported unexpected (not reflected in the latest approved label) adverse event (AE)/drug reaction (ADR)

    Time frame: Up to approximately 16 Weeks

  3. Percentage (%) of participants who reported known (labeled) ADR

    Percentage (%) of participants who reported known (labeled) ADR

    Time frame: Up to approximately 16 Weeks

  4. Percentage (%) of participants who reported non-serious AE/ADR

    Percentage (%) of participants who reported non-serious AE/ADR

    Time frame: Up to approximately 16 Weeks

  5. Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the Risk Management Plan (RMP)

    Percentage (%) of participants who reported the events related to important potential risks and missing information defined in the RMP

    Time frame: Up to approximately 16 Weeks

  6. Percentage (%) of participants with AE: overall summary

    Percentage (%) of participants with AE: overall summary

    Time frame: Up to approximately 16 Weeks

  7. Percentage (%) of participants with common (>=5%) AE

    Percentage (%) of participants with common (\>=5%) AE

    Time frame: Up to approximately 16 Weeks

  8. Percentage (%) of participants with AE leading to treatment discontinuation

    Percentage (%) of participants with AE leading to treatment discontinuation

    Time frame: Up to approximately 16 Weeks

  9. Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment

    Percentage (%) of participants who reported treatment-related AE per the investigator causality assessment

    Time frame: Up to approximately 16 Weeks

  10. Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment

    Percentage (%) of participants who reported treatment-related serious AE per the investigator causality assessment

    Time frame: Up to approximately 16 Weeks

07

Study locations

36 of 36 sites recruiting
  • On Hospital /ID# 285157
    Busan, Busan Gwang Yeogsi 47261, South Korea
    Recruiting
  • Ryu Sang Hyo Neurosurgery Clinic /ID# 284804
    Busan, Busan Gwang Yeogsi 48496, South Korea
    Recruiting
  • Dong-A University Medical Center /ID# 275321
    Busan, Busan Gwang Yeogsi 49201, South Korea
    Recruiting
  • Chungnam National University Hospital /ID# 284724
    Daejeon, Daejeon Gwang Yeogsi 35015, South Korea
    Recruiting
  • Chuncheon Sacred Heart Hospital /ID# 275315
    Gangwon-do, Gang Weondo 24253, South Korea
    Recruiting
  • Chonnam National University Hospital /ID# 275318
    Gwangju, Gwangju Gwang Yeogsi 61469, South Korea
    Recruiting
  • Korea University Ansan Hospital /ID# 284725
    Ansan-si, Gyeonggido 15355, South Korea
    Recruiting
  • Inje University - Ilsan Paik Hospital /ID# 280738
    Goyang, Gyeonggido 10380, South Korea
    Recruiting
  • National Health Insurance Corporation Ilsan Hospital /ID# 285128
    Goyang-si, Gyeonggido 10444, South Korea
    Recruiting
  • Hallym University Dongtan Sacred Heart Hospital /ID# 273581
    Hwaseong, Gyeonggido 18450, South Korea
    Recruiting
  • Hallym University Dongtan Sacred Heart Hospital /ID# 280737
    Hwaseong, Gyeonggido 18450, South Korea
    Recruiting
  • Teunteun Hospital /ID# 284730
    Hwaseong-si, Gyeonggido 18379, South Korea
    Recruiting
  • Life Neurology Clinic /ID# 284729
    Hwaseong-si, Gyeonggido 18478, South Korea
    Recruiting
  • Gachon University Gil Medical Center /ID# 284571
    Incheon, Gyeonggido 21565, South Korea
    Recruiting
  • Seoul National University Bundang Hospital /ID# 284508
    Seongnam-si, Gyeonggido 13620, South Korea
    Recruiting
  • Ajou University Hospital - Suwon-si /ID# 284574
    Suwon, Gyeonggido 16499, South Korea
    Recruiting
  • Hwahong Hospital /ID# 284803
    Suwon, Gyeonggido 16630, South Korea
    Recruiting
  • Uijeongbu Eulji Medical Center - Eulji University /ID# 284855
    Uijeongbu-si, Gyeonggido 11759, South Korea
    Recruiting
  • Yongin Severance Hospital /ID# 284570
    Yongin-si, Gyeonggido 16995, South Korea
    Recruiting
  • Daegu Catholic University Medical Center /ID# 284728
    Daegu, Gyeongsangbuk-do 42472, South Korea
    Recruiting
  • Keimyung University Dongsan Hospital /ID# 284727
    Daegu, Gyeongsangbuk-do 42601, South Korea
    Recruiting
  • Changwon Fatima Hospital /ID# 284572
    Changwon-si, Gyeongsangnam-do 51394, South Korea
    Recruiting
  • The Catholic University of Korea, Incheon St. Mary's Hospital /ID# 284568
    Incheon, Incheon Gwang Yeogsi 21431, South Korea
    Recruiting
  • Inha University Hospital /ID# 275320
    Incheon, Incheon Gwang Yeogsi 21565, South Korea
    Recruiting
  • Wonkwang University Hospital /ID# 284567
    Iksan, Jeonrabugdo 54538, South Korea
    Recruiting
  • Jeonbuk National University Hospital /ID# 273583
    Jeonju, Jeonrabugdo 54907, South Korea
    Recruiting
  • Nowon Eulji Medical Center, Eulji University /ID# 275316
    Seoul, Seoul Teugbyeolsi 01830, South Korea
    Recruiting
  • Korea University Anam Hospital /ID# 284726
    Seoul, Seoul Teugbyeolsi 02841, South Korea
    Recruiting
  • Seoul National University Hospital /ID# 271892
    Seoul, Seoul Teugbyeolsi 03080, South Korea
    Recruiting
  • Seoul National University Hospital /ID# 272638
    Seoul, Seoul Teugbyeolsi 03080, South Korea
    Recruiting
  • Kangbuk Samsung Hospital /ID# 271893
    Seoul, Seoul Teugbyeolsi 03181, South Korea
    Recruiting
  • Yonsei University Health System Severance Hospital /ID# 272639
    Seoul, Seoul Teugbyeolsi 03722, South Korea
    Recruiting
  • Samsung Medical Center /ID# 272640
    Seoul, Seoul Teugbyeolsi 06351, South Korea
    Recruiting
  • Ewha Womans University Medical Centre /ID# 275317
    Seoul, Seoul Teugbyeolsi 07985, South Korea
    Recruiting
  • Korea University Guro Hospital /ID# 284569
    Seoul, Seoul Teugbyeolsi 08308, South Korea
    Recruiting
  • Hallym University Kangdong Sacred Heart Hospital /ID# 284573
    Seoul, 05355, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for May 2029, 56 months after the start.

Of 160 observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2024
First posted
Sep 19, 2024
StartActual
Sep 24, 2024
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06603558
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Sep 24, 2024
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Jul 22, 2026

Study contacts

Celine Im
Contact
celine.im@abbvie.com
+82-10-2230-3629
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion